感染症学雑誌第77巻第8号
|
|
|
- あいね しろみず
- 7 years ago
- Views:
Transcription
1 1
2 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae
3 pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp
4 pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ pbp3 ftsi β βpbp3 ftsi β pbp3 ftsi β pbp3 ftsi 3
5
6 4
7 5
8
9 et al et al et al et al β β et al et al et
10 al et al et al et al et al et al et al Streptococcus pneumoniae et al et al et al et al et al et al et al et al
11
日本化学療法学会雑誌第56巻第S-1号
Key words Streptococcus pneumoniae µ µ H F Cl H H N N H N F COOH O Fig.1. Sitafloxacinstructure. I γ S. pneumoniae Haemophilus influenzae Table1. Observationandtestschedule Observation/Tests Informedconsent
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
2 7 ( ) µ 
日本化学療法学会雑誌第57巻第4号
Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.
日本化学療法学会雑誌第59巻第6号
P P Streptococcus pneumoniae S. pneumoniae Key words Streptococcus pneumoniae Fig. 1. Capsular swelling reaction of S. pneumoniae type 6B. Cells are stained dark blue using a methylene blue. Capsule is
2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
取扱説明書 [プロジェクターユニット F01]
![取扱説明書 [プロジェクターユニット F01]](/thumbs/41/22784697.jpg "取扱説明書 [プロジェクターユニット F01]")
1 2 3 4 5 6 7 8 9 10 11 12 a b c d a b c d a b c g h i d j e l f k m a b c d e f g K h J i V j k 13 l m 14 15 1 a 2 b b a 1 16 1 ab a b 2 ab a b 17 3 4 ab a b 1 2 18 1 a b 19 2 3 20 1 K 1 K 1 2 3 a b a
産衛誌57-4たより.indb
A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al
172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1
4 16 1 10:0010 : 24 1F Annex 1! 2 15:0015 : 24 1F Annex 1!! 10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 ! 2 10:0010 : 28 1F Annex 1 3 15:0015 : 28 1F Annex 1 4 10:3010 : 58 1F Annex 1 1 15:3015
日歯雑誌（Ｈ２８・８月号）別刷り／ポスターセッション とびら
α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α
_0212_68<5A66><4EBA><79D1>_<6821><4E86><FF08><30C8><30F3><30DC><306A><3057><FF09>.pdf
内科９６巻３号★／ＮＡＩ３‐１（第２２回試験問題）
µ µ α µ µ µ µ µ µ β β α γ µ Enterococcus faecalis Escherichia coli Legionella pneumophila Pseudomonas aeruginosa Streptococcus viridans α β 正解表正解記号問題 No. 正解記号問題 No. e(4.5) 26 e 1 a(1.2) 27 a 2
2.2 (1967) (1997,2003) 2.2 ( ) 11
( ) 2.1 10 2.2 (1967) (1997,2003) 2.2 ( ) 11 12 ( ) 90150 (684) (887) (1099) (1361) (1605) (1707) (1854) 21(1946) 8 2.3 (1854) 13 (1997) (1854.12.23) (M8.4) (24 ) (M8.4) 70,000 3000 ( ) 7 2 3 3 (,1997)
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon
Feb. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 1 1 2008 2009 2011 10 25 2008 6 2009 4 Streptococcus pneumoniae 377 penicillin-binding protein: PBP 2004 S. pneumoniae 160 2 2 THE JAPANESE JOURNAL OF
original: 2011/11/5 revised: 2012/10/30, 2013/12/ : 2 V i V t2 V o V L V H V i V i V t1 V o V H V L V t1 V t2 1 Q 1 1 Q
original: 2011/11/5 revised: 2012/10/30, 2013/12/2 1 1 1: 2 V i V t2 V o V L V H V i V i V t1 V o V H V L V t1 V t2 1 Q 1 1 Q 2 2 1 2 1 c 2013 2 2: V i Q 1 I C1 V C1 V B2 I E V E V E Q 1 Q 1 Q 2 Q 2 Q
3/4/8:9 { } { } β β β α β α β β
α β : α β β α β α, [ ] [ ] V, [ ] α α β [ ] β 3/4/8:9 3/4/8:9 { } { } β β β α β α β β [] β [] β β β β α ( ( ( ( ( ( [ ] [ ] [ β ] [ α β β ] [ α ( β β ] [ α] [ ( β β ] [] α [ β β ] ( / α α [ β β ] [ ] 3
ブック2
30 1 15 1 39 43 56 43 MRSA MRSA 4 MRSA 1 4 1 16 6 2 PRSP BLNAR PCR 21 17.6 16.5 10 8.2 30 20 3 1 2 3 4 5 6 PRSP 1980 10 1 1987 PISP 1. PRSP-BLNARR R PRSP 1994 1996 PRSP 30 2000 50 PISP 40 10 15 BLPAR 1985
日本目録規則1987年版改訂2版第2章図書改定案
2.0.1 2.0.2 2.0.3 2.0.4 2.0.5 2.0.6 2.1.1 2.1.2 2.1.3 2.1.4 2.1.5 2.2.1 2.2.2 2.2.3 2.2.4 2.4.1 2.4.2 2.4.3 2.4.4 2.5.1 2.5.2 2.5.3 2.5.4 2.6.1 2.6.2 2.6.3 2.6.4 2.6.5 ISSN 2.6.6 2.6.7 2.7.1 2.7.2 2.7.3
日本化学療法学会雑誌第57巻第1号
In vitro Streptococcus pneumoniae Escherichia coli in vitro Streptococcus pneumoniae Escherichia coli µs. pneumoniae E. coli µ Key words in vitrostreptococcus pneumoniae Escherichia coli Escherichia coli
第82 回日本感染症学会総会学術集会後抄録（I）
β Aspergillus Aspergillus β in vitro in vivo α γ α γδ Streptococcus suis S. suis Chlamydia trachomatis C. trachomatis C. trachomatis C. trachomatis Chlamydia Helicobacter pylori H. pylori H. pylori H.
MI( MI() 100% 100% 75% 75% 33% 75% 60% 40% 25% 60% 1 2 3 4 5 6 7 8 9 () 12 () () () !! 1. 2. 3. 1. 2. () () () 3-5% ex. ex. 11 ex. () ex. ex. : ex. : (insula) () () ( 2009 ) () ( ) YES! ()
第１４〜１５回 Ｔ細胞を介する免疫系.pptx
MBL CD8 CD4 8.1 8.2 5.20 8.3 8.4 8.5 8.6 8.7 8.8 8.9 8.10 8.18 B7 CD28 CD28 B7 CD28 8.13 2.22 NK Toll(TLR) LBP! LPS dsrna ssrna TLR1/2/6! TLR4 TLR5 TLR3 TLR7/9 CD14! JNK/p38! MyD88! IRAK! TRAF! NFκB! TNF-α
研修コーナー
l l l l l l l Department of Obstetrics and Gynecology, Fukui Medical University, Fukui l l l l l l µ l β β l α l µ µ l l l l Department of Obstetrics and Gynecology, Gifu University School of Medicine,
untitled
1309 06 06 020306026ｧ8 BO06EIO08 6ﾑ8 A04 ﾌ6ｾ4, 18: 119-131, 2006 ﾞ03 ﾞ6ｾ4 ﾒ ﾌ09 ﾇ6ｾ4 ﾇ 01036ｧ80409 07020600060203086 506 020607 02 06 0707apple020ｸ70109 070208046ｧ80ｹ0 02080ｸ7 apple07000ｸ700080706fi02080202080ｸ7
dy = sin cos y cos () y () 1 y = sin 1 + c 1 e sin (3) y() () y() y( 0 ) = y 0 y 1 1. (1) d (1) y = f(, y) (4) i y y i+1 y i+1 = y( i + ) = y i
007 8 8 4 1 1.1 ( ) (partial differential equation) (ordinary differential equation) 1 dy = f(, y) (1) 1 1 y() (1) y() (, y) 1 dy = sin cos y cos () y () 1 y = sin 1 + c 1 e sin (3) 1 1 5 y() () y() y(
ｎｓｇ０４－２８／ｋｙ２０８６８４３５６１０００４３０７７
δ!!! μ μ μ γ UBE3A Ube3a Ube3a δ !!!! α α α α α α α α α α μ μ α β α β β !!!!!!!! μ! Suncus murinus μ Ω! π μ Ω in vivo! μ μ μ!!! ! in situ! in vivo δ δ !!!!!!!!!! ! in vivo Orexin-Arch Orexin-Arch !!
がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性
2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
日本化学療法学会雑誌第60巻第4号
Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Key words β Streptococcus pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae μ μ S. pneumoniae H. influenzae S. pneumoniae
3 4 6 7 8 9 10 12 14 2 3
3 4 6 7 8 9 10 12 14 2 3 POINT 4 5 3053 1323 4 7 6 1 1 4 7 Yamada N. et al : Int J Cardiol. 98, 409-411, 2005 6 7 POINT 0 20 40 60 80 100 60 80 Ota M. et al: Heart Vessels. 17, 7-11,2002 40 60 20 50 15
日本分子第5巻2号_15特別講演・シンポジウム.indd
25 JSMI Report JSMI Report 26 41 JSMI Report JSMI Report 42 JSMI Report 54 55 JSMI Report JSMI Report 56 57 JSMI Report JSMI Report 58 59 JSMI Report JSMI Report 60 61 JSMI Report β JSMI Report 62 63 JSMI
THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 STFX mg mg mg mg mg 1
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 175 29 1 2 2 2 2 2 3 4 4 5 5 2 2 1 2 3 4 5 2014 4 15 STFX 50 mg 10% 2011 8 1 100 mg 1 1 2011 12 2013 5 226 1,186 1,089 1,069 2.11% 23/1,089 1.10% 12/1,089
2
C o r n e l i u s The Science of E m o t i o n I z a r d The Psychology of Emotions Rusalova et al. Schwartz et al E M G 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 The science of emotion The psychology
I II III IV V
I II III IV V N/m 2 640 980 50 200 290 440 2m 50 4m 100 100 150 200 290 390 590 150 340 4m 6m 8m 100 170 250 µ = E FRVβ β N/mm 2 N/mm 2 1.1 F c t.1 3 1 1.1 1.1 2 2 2 2 F F b F s F c F t F b F s 3 3 3
NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml
NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008
#A A A F, F d F P + F P = d P F, F y P F F x A.1 ( α, 0), (α, 0) α > 0) (x, y) (x + α) 2 + y 2, (x α) 2 + y 2 d (x + α)2 + y 2 + (x α) 2 + y 2 =
#A A A. F, F d F P + F P = d P F, F P F F A. α, 0, α, 0 α > 0, + α +, α + d + α + + α + = d d F, F 0 < α < d + α + = d α + + α + = d d α + + α + d α + = d 4 4d α + = d 4 8d + 6 http://mth.cs.kitmi-it.c.jp/
600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN
日本化学療法学会雑誌第50巻第6号
13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
1 3 1.1.......................... 3 1............................... 3 1.3....................... 5 1.4.......................... 6 1.5........................ 7 8.1......................... 8..............................
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
感染症学雑誌第80巻第6号
Streptococcus pyogenes Streptococcus Streptococcus pyogenes Streptococcus dysgalactiae equisimilis S. pyogenes S. pyogenes S. dysgalactiae equisimilis S. pyogenes S. dysgalactiae equisimilis S. pyogenes
数学概論I
{a n } M >0 s.t. a n 5 M for n =1, 2,... lim n a n = α ε =1 N s.t. a n α < 1 for n > N. n > N a n 5 a n α + α < 1+ α. M := max{ a 1,..., a N, 1+ α } a n 5 M ( n) 1 α α 1+ α t a 1 a N+1 a N+2 a 2 1 a n
日本糖尿病学会誌第58巻第1号
α β β β β β β α α β α β α l l α l μ l β l α β β Wfs1 β β l l l l μ l l μ μ l μ l Δ l μ μ l μ l l ll l l l l l l l l μ l l l l μ μ l l l l μ l l l l l l l l l l μ l l l μ l μ l l l l l l l l l μ l l l l
437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
07-第4章村上英吾.indd
1990 1990 2007 2000 2007 9 3 46 1 2 1960 1 1984 60 3 1970 4 2000 2003 2009 2011 12007 2 2007 12 25 2 1 2007 10 19 1 5 2007 12 11 3 Bradshaw, J., et. al., 2008. 41982 47 2010 5 2011 2004 2004 1994 5 2009
スライド 1
ファイザー KK 社内勉強会 肺炎球菌ワクチンと マクロライド耐性マイコプラズマ 肺炎球菌はどのように進化していくのか? マクロライド耐性マイコプラズマは何故発生するか? 東栄病院小児科菊田英明平成 28 年 9 月 8 日 肺炎球菌 : Streptococcus pneumoniae 肺炎球菌はどのように進化していくのか? 莢膜による免疫機構の回避 肺炎球菌 莢膜 肺炎球菌 莢膜 補体 抗体 食細胞
cit_5.vp
132007 000606020902010608 0606ｨｬ49, 015 0903090208 FtsZ 06 000606020806010305 07 0908080603040607 08 06. 03. 00ｨｨ03ｨｪ07ｨｺ0609, 05. 01. 090608010902ｨｪｨｨｨｮ09 06. 03. 00ｨｨ03ｨｪ07ｨｺ0609, 05. 01. 090608010902ｨｪｨｨｨｮ09
EPSON LP-8900ユーザーズガイド
3 4 5 6 7 8 abc ade w p s 9 10 s s 11 p 12 p 13 14 p s 15 p s A B 16 w 17 C p 18 D E F 19 p w G H 20 A B 21 C s p D 22 E s p w 23 w w s 24 p w s 25 w 26 p p 27 w p s 28 w p 29 w p s 30 p s 31 A s B 32
1 Edward Waring Lagrange n {(x i, y i )} n i=1 x i p i p i (x j ) = δ ij P (x) = p i p i (x) = n y i p i (x) (1) i=1 n j=1 j i x x j x i x j (2) Runge
Edwrd Wring Lgrnge n {(x i, y i )} n x i p i p i (x j ) = δ ij P (x) = p i p i (x) = n y i p i (x) () n j= x x j x i x j (2) Runge [] [2] = ξ 0 < ξ < ξ n = b [, b] [ξ i, ξ i ] y = /( + 25x 2 ) 5 2,, 0,,
日本糖尿病学会誌第58巻第3号
l l μ l l l l l μ l l l l μ l l l l μ l l l l l l l l l l l l l μ l l l l μ Δ l l l μ Δ μ l l l l μ l l μ l l l l l l l l μ l l l l l μ l l l l l l l l μ l μ l l l l l l l l l l l l μ l l l l β l l l μ
THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 azithromycin AZM, 500 mg 37.0 C communityacquired pneumonia; CAP C C-reactive protein; CRP 9
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 193 47 1 1 1 1 3 3 4 1 5 6 1 2 5 5 1 2 4 1 6 1 3 7 2 1 1 2 3 4 5 6 7 2014 4 14 azithromycin; AZM 15 community-acquired pneumonia; CAP AZM A-DROP CAP AZM
スライド 1
e-japan -2004 1 Integrated Healthcare Network (IHN) e-icusentara Sentara Healthcare T C I H A H I 0 5 0 3 T C I H A H I 2 10 6 1 0 1935 40 45 50 55 60 65 70 75 80 85 90 95 2000 K. Matsuoka et al.
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
: : 2001227 : 2
: : 2001227 : 2 mg/100gmg/100g mg/100g 3 10/102006 12/05 2/19, 2007 Zn 63 98 4 10% 5 Ramesh et al. 2004 6 Connoly et al. 2002 A IRT 7 8 2.11mg/100g143%56% 9 10 Alaria praelonga 11 2 12 13 14 15 16 1 1
idwr2008_21
VanC 521 0.63 0.24 2.12 2.27 1.07 0.98 1.75 0.70 27.24 0.76 1.16 0.35 1.26 0.71 2SD 1SD 1SD 2SD A SD 0.21 0.58 3.02 7.02 1.89 0.70 0.20 0.72 0.11 0.37 0.43 0.04 0.79 0.39 5515 6.19 Streptococcus pyogenes
untitled
c OR 21 OR 1. 21 21 IoT OR OR OR 260 8672 1 8 1 OR 2. 2.1 public health [1] communicable (infectious) diseases vehicle burden HIV/AIDS (SARS) 258 60 Copyright c by ORSJ. Unauthorized reproduction of this
2
1 2 3 4 5 6 7 8 9 10 11 12 13 14 10mSv 15 16 17 4.46 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 3.8 2.07 2.91 1.37 2.3 1.31 1.84 1.56 1.2 1.33 2.03 0.5 1000 4000mSv 1000 4000mSv Preston et al. Radiat Res 168: 1 64,
28_04_斎藤正章.indd
37 2820103743,. 282010.3743 純 粋 持 株 会 社 における 経 営 管 理 上 の 課 題 1 2 ABSTR ACT...... 1 2 1 38 2 1 1 3 2 1 1 4 5 6 7 8 1 2 1 1992.269 39 1 1 1 2 9 1 2 3 123 13 2 1995.268 40,.1995 3 10, et al.1995 2 1950 2
会津若松市民の運動行動における変化ステージの評価
2 Bandura1977 2000 Bandura 50 36 3 4 MarcusSimkin1993 2002 6 6 6 6 1995 2000.81 1998 1995 2000.91 2000 5 .65 1986.83 Marcus et al1992 2002 Pros.81 Cons.80 Pros Cons Pros Cons 6 7 8 9 10 11 12 13 5 Tukey
1. - - - 2 - - 3 - - 4 - 1 Muser KT, Bond GR, Drake RE, et al(1998). Model of community care for severe mental illness: A review of research on case management. Schizophrenia Bulletin, 24(1): 33-74. -
主要耐性菌の概要.ppt
1. 2. KPC- 3. NDM-1-β- 4. CTX-M-15ST131 CTX-M-9CTX-M-14 5. Oct. 1, 2010 1SSI 2.2008 3Acinetobacter 4 MRSA PRSP GP VRE MR-S. aureus (erm) PRGBS MR-S. pneum (mefe) MDR-TB XDR-TB 1970 GN 1980 ESBL 1990 EM-R
プラズマ核融合学会誌１月【８３－２】／講座２－３
2.3 Plasma Flow Measurements Spectroscopic Methods KADO Shinichiro author s e-mail: kado@q.t.u-tokyo.ac.jp Czerny-Turner GN: grating normalmn: mount normalfn: facet normal. f L L Fig. 3 μ μ in-situ μ
idwr2015_24
S. boydii S. sonnei K. pneumoniae E. aerogenes E. coli E. cloacae E. aerogenes K. pneumoniae 5 2.40 0.19 0.76 1. 1. 0.34 0.61 0.51 0.62 0.37 0.45 1.49 2SD 1SD 1SD 2SD A SD 0.17 0.77 55 1.22 4. 3.64 7.